Three agents are approved, and more studies are underway ...

IgG is the predominant antibody isotype found in the female genital tract and serves as an important defence mechanism against genital tract infections. In a recent study, Zili et al. have shown that ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

Immunoglobin G (IgG) antibodies play an important role in our body’s defense against viruses and bacteria, but they also contribute to autoimmune diseases. Working with investigators at Brigham and ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting treatments for generalized myasthenia gravis (gMG) in adults. The phase ...

Immunovant has advanced its mission to claim an unoccupied area of the competitive anti-FcRn space, reporting phase 2 data that support its attempt to be the first to market in Graves’ disease. The ...

Please provide your email address to receive an email when new articles are posted on . FcRn receptors have received FDA approvals in generalized myasthenia gravis. Studies of FcRn receptors in RA and ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin ...

The approval of Orthoclone OKT3 ® (muromonab-CD3) in 1986 marked the first appearance of monoclonal antibodies in the clinic. In the over 20 years since, more than 70 antibodies have been approved for ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering ...

Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of FcRn-Targeted Therapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about FcRn-Targeted ...